share_log

Roth MKM Reinstates Buy on Chemomab Therapeutics, Maintains $7 Price Target

Benzinga ·  Dec 19, 2023 22:14

Roth MKM analyst Dylan Dupuis reinstates Chemomab Therapeutics (NASDAQ:CMMB) with a Buy and maintains $7 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment